ARCA biopharma (ABIO) Awarded U.S. Patent for Methods of Treatment with Bucindolol

ARCA biopharma, Inc. (Nasdaq: ABIO) announced that the U.S. Patent and Trademark Office (USPTO) has issued a patent on methods for treating patients with bucindolol based on genetic targeting and focused on a specific genotype – homozygous wildtype for Deletion 322-325 in the alpha-2C adrenergic receptor. The patent (USP# 8,080,578) entitled “Methods for Treatment with Bucindolol Based on Genetic Targeting,” provides protection in the United States for this novel approach to treating patients with bucindolol.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Boeing names Ryan Shedd as new SVP and controller
• Nu Skin EVP of global sales takes medical leave
• Lazard Global Total Return fund declares $0.1534 monthly distribution